79 related articles for article (PubMed ID: 29345812)
21. Avian erythroleukemia: a model for corepressor function in cancer.
Rietveld LE; Caldenhoven E; Stunnenberg HG
Oncogene; 2001 May; 20(24):3100-9. PubMed ID: 11420726
[TBL] [Abstract][Full Text] [Related]
22. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
23. Core-binding factor: a central player in hematopoiesis and leukemia.
Speck NA; Stacy T; Wang Q; North T; Gu TL; Miller J; Binder M; Marín-Padilla M
Cancer Res; 1999 Apr; 59(7 Suppl):1789s-1793s. PubMed ID: 10197598
[TBL] [Abstract][Full Text] [Related]
24. Regulation and regulatory parameters of histone modifications.
Davie JR; Chadee DN
J Cell Biochem Suppl; 1998; 30-31():203-13. PubMed ID: 9893272
[TBL] [Abstract][Full Text] [Related]
25. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT.
Huynh KD; Bardwell VJ
Oncogene; 1998 Nov; 17(19):2473-84. PubMed ID: 9824158
[TBL] [Abstract][Full Text] [Related]
26. A feed-forward repression mechanism anchors the Sin3/histone deacetylase and N-CoR/SMRT corepressors on chromatin.
Vermeulen M; Walter W; Le Guezennec X; Kim J; Edayathumangalam RS; Lasonder E; Luger K; Roeder RG; Logie C; Berger SL; Stunnenberg HG
Mol Cell Biol; 2006 Jul; 26(14):5226-36. PubMed ID: 16809761
[TBL] [Abstract][Full Text] [Related]
27. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
28. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract][Full Text] [Related]
29. The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia.
Sotoca AM; Prange KH; Reijnders B; Mandoli A; Nguyen LN; Stunnenberg HG; Martens JH
Oncogene; 2016 Apr; 35(15):1965-76. PubMed ID: 26148230
[TBL] [Abstract][Full Text] [Related]
30. ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias.
D'Amato L; Dell'Aversana C; Conte M; Ciotta A; Scisciola L; Carissimo A; Nebbioso A; Altucci L
Epigenetics; 2015; 10(1):6-18. PubMed ID: 25494542
[TBL] [Abstract][Full Text] [Related]
31. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts.
Gozzini A; Rovida E; Dello Sbarba P; Galimberti S; Santini V
Cancer Res; 2003 Dec; 63(24):8955-61. PubMed ID: 14695213
[TBL] [Abstract][Full Text] [Related]
32. Promoter specific sensitivity to inhibition of histone deacetylases: implications for hormonal gene control, cellular differentiation and cancer.
Dressel U; Renkawitz R; Baniahmad A
Anticancer Res; 2000; 20(2A):1017-22. PubMed ID: 10810390
[TBL] [Abstract][Full Text] [Related]
33. Histone H4 N-terminal acetylation in Kasumi-1 cells treated with depsipeptide determined by acetic acid-urea polyacrylamide gel electrophoresis, amino acid coded mass tagging, and mass spectrometry.
Zhang L; Su X; Liu S; Knapp AR; Parthun MR; Marcucci G; Freitas MA
J Proteome Res; 2007 Jan; 6(1):81-8. PubMed ID: 17203951
[TBL] [Abstract][Full Text] [Related]
34. Trans-repressive effect of NUP98-PMX1 on PMX1-regulated c-FOS gene through recruitment of histone deacetylase 1 by FG repeats.
Bai XT; Gu BW; Yin T; Niu C; Xi XD; Zhang J; Chen Z; Chen SJ
Cancer Res; 2006 May; 66(9):4584-90. PubMed ID: 16651408
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.
Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD
J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors--a new tool to treat cancer.
Somech R; Izraeli S; J Simon A
Cancer Treat Rev; 2004 Aug; 30(5):461-72. PubMed ID: 15245778
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo.
Atsumi A; Tomita A; Kiyoi H; Naoe T
Biochem Biophys Res Commun; 2006 Jul; 345(4):1471-80. PubMed ID: 16730330
[TBL] [Abstract][Full Text] [Related]
38. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
39. Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development.
Vishwakarma BA; Nguyen N; Makishima H; Hosono N; Gudmundsson KO; Negi V; Oakley K; Han Y; Przychodzen B; Maciejewski JP; Du Y
Leukemia; 2016 Jan; 30(1):200-8. PubMed ID: 26205084
[TBL] [Abstract][Full Text] [Related]
40. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
Altucci L; Clarke N; Nebbioso A; Scognamiglio A; Gronemeyer H
Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
